FDA Clears Heart Disease Trial At Boston Childrens Hospital
Filed with ASX · · 2 pages · English
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallEarlier from Mesoblast
- Process Initiated For CHF P3 Interim Analysis
- Mesoblast Raises US$40 Million
- Durable Three Year Outcomes in Disc Disease
- FDA Grants Mesoblast Fast Track Designation For GVHD
- Positive Nine Month RA Results For Mesoblast Cell Therapy
Later from Mesoblast
- Mesoblast Receives A$3.7m From Aus Govt For R&D
- Successful Interim Analysis in Phase 3 Heart Failure Trial
- Third Quarter Financial Results On Form 6-K
- MSB Provides Q3 Operational Highlights and Financial Results
- Mesoblast RA Results Presented At EULAR Congress
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast